vVARDIS Holding AG has taken a major step towards going public by filing an amended registration statement for its initial public offering (IPO). This filing, submitted on November 12, 2026, represents a significant milestone for the company as it seeks to raise capital and expand its operations in the competitive surgical and medical instruments sector.
The company plans to offer 8,333,334 Class A ordinary shares at an expected price range of $21.00 to $24.00 per share. Additionally, underwriters may purchase up to 1,250,000 additional shares to cover over-allotments. This move indicates vVARDIS's confidence in its market position and growth potential.
Background
vVARDIS Holding AG is classified under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. The company is based in Zug, Switzerland, and operates as an emerging growth company. It has been actively preparing for its IPO, having filed several forms with the SEC leading up to this amended registration statement.
Recent filings include multiple Form 4 submissions, indicating insider trading activity, and a Form S-8, which typically relates to employee benefit plans. The company’s stock will trade under the ticker symbol "VVVV" on the New York Stock Exchange.
What the Filing Says
The amended registration statement outlines the structure of the share offering, including the conversion of existing share capital into two classes: Class A ordinary shares and Class B voting rights shares. Each Class B share will carry ten times the voting power of a Class A share, allowing the founders, Haley and Goly Abivardi, to maintain significant control over the company’s decisions.
According to the filing, "Following this offering, our Founders will control ordinary shares representing 87.6% of the total voting power of our share capital, assuming no exercise of the underwriters’ option to purchase Class A ordinary shares to cover over-allotments." This provision ensures that the founders can influence key corporate actions, including board elections and amendments to corporate governance documents.
Impact
This IPO could significantly affect various stakeholders, including potential investors looking to enter the surgical and medical instruments market. The offering not only provides vVARDIS with the necessary capital to expand its operations but also signals to competitors the company's readiness to compete on a larger scale.
With the founders retaining a majority of voting power, strategic decisions will likely reflect their vision for the company, which may impact employee morale and investor confidence in the long term.
What's Next
The next steps for vVARDIS Holding AG involve finalizing the terms of the IPO and awaiting the effective date of the registration statement. The filing does not specify a timeline for when the shares will be available for trading, but it indicates that the company is eager to proceed as soon as practicable following the effective date.
As the IPO process unfolds, market participants will be closely watching vVARDIS’s performance and the broader implications for the surgical and medical instruments industry.
Read Next
TruGolf Holdings files S-1 for potential public offering
ContextLogic Holdings files S-1 for potential public offering
BIO-key International files amended registration for stock offering
Tongda International Group Co. files for IPO on Nasdaq
ConnectM Technology Solutions files amended registration statement
bioAffinity Technologies files registration statement for stock










